[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.158.173.184. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
Book and Media Reviews
February 14, 2007

Overdose: How Excessive Government Regulation Stifles Pharmaceutical Innovation

Author Affiliations
 

Book and Media Reviews Section Editor: John L. Zeller, MD, PhD, Fishbein Fellow, JAMA.

JAMA. 2007;297(6):644-648. doi:10.1001/jama.297.6.646

Since the cover of Overdose promotes it as “a healthy corrective” to the “often one-sided criticism” that the pharmaceutical industry has come under, I looked forward to reading a spirited response to Angell,1 Kassirer,2 and others. However, Epstein does not take on these critics directly. As a legal scholar, he examines the judicial and political aspects of the regulation of the discovery, approval, marketing, and liability of new pharmaceuticals in the United States.

First Page Preview View Large
First page PDF preview
First page PDF preview
×